Relmada Therapeutics

Yahoo Finance • 12 days ago

Relmada regains Nasdaq compliance on minimum bid price

* Relmada Therapeutics (NASDAQ:RLMD [https://seekingalpha.com/symbol/RLMD]) on Tuesday said it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. * The company’s shares maintained a closing bid price of $1.00 o... Full story

Yahoo Finance • 18 days ago

Relmada Issues Mid-Year CEO Letter to Shareholders

CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous... Full story

Yahoo Finance • 25 days ago

On Wednesday, there are stocks with unusual volume. Let's take a look.

Which stocks have an unusual volume on Wednesday? [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PSNYW [https://www.chartmill.com/stock/quote/PSNYW/profile] 25.04% POLESTAR AUTO CLASS C-1 ADS (NASDAQ:PSNY... Full story

Yahoo Finance • 2 months ago

Relmada outlines 2026 trial launches for NDV-01 and sepranolone as pipeline advances

Earnings Call Insights: Relmada Therapeutics, Inc. (RLMD) Q2 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted the addition of two product candidates, NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compu... Full story

Yahoo Finance • 2 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system in... Full story

Yahoo Finance • 3 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent... Full story

Yahoo Finance • 2 years ago

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Relmada Therapeutics, Inc. (NASDAQ:RLMD), it sends a favourable message to the company's shareholders... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Re... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shift4 Payments, Inc. (NYSE: FOUR), Waldencast Plc (NASDAQ: WALD), Ch... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Seagate Technology Holdings Plc (NASDAQ: STX), Chegg, Inc. (NYSE: CHG... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Relmada, DoubleVerify, Sanmina, and JinkoSolar and Encourages Investors to Contact the Firm

NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), DoubleVerify Holdings, Inc.... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Seagate, Chegg, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), Seagate Technology Holdings Plc (NASDA... Full story

Yahoo Finance • 2 years ago

RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD

NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Relmada Therapeutics, Inc. (NASDAQ: RLMD) result... Full story

Yahoo Finance • 2 years ago

Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm

NEW YORK, May 14, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ: FOX, FOXA), Cutera, Inc. (NASDAQ: CUTR), and... Full story

Yahoo Finance • 2 years ago

RLMD INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) concerning possible violations of federal sec... Full story

Yahoo Finance • 3 years ago

10 Most Promising Psychedelic Stocks According To Analysts

In this article, we discuss 10 most promising psychedelic stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Psychedelic Stocks According To Analysts. Psychedelic drugs encompass a r... Full story

Yahoo Finance • 3 years ago

Relmada’s stock tumbles 80% after its depressive disorder drug failed a late-stage study

MARKET PULSE Shares of Relmada Therapeutics Inc. (RLMD) fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Pha... Full story

Yahoo Finance • 3 years ago

What Type Of Shareholders Own The Most Number of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares?

If you want to know who really controls Relmada Therapeutics, Inc. (NASDAQ:RLMD), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to ha... Full story